Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection
NCT04296695Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Peking Union Medical College Hospital. Started Jul 2021; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04296695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296695.